BR112012024676A2 - peptídeo, método para tratar, composição, e, substrato - Google Patents

peptídeo, método para tratar, composição, e, substrato

Info

Publication number
BR112012024676A2
BR112012024676A2 BR112012024676A BR112012024676A BR112012024676A2 BR 112012024676 A2 BR112012024676 A2 BR 112012024676A2 BR 112012024676 A BR112012024676 A BR 112012024676A BR 112012024676 A BR112012024676 A BR 112012024676A BR 112012024676 A2 BR112012024676 A2 BR 112012024676A2
Authority
BR
Brazil
Prior art keywords
amino acids
substrate
treating composition
peptide
peptide method
Prior art date
Application number
BR112012024676A
Other languages
English (en)
Other versions
BR112012024676B1 (pt
Inventor
Cedric Charrier
Deborah O'neil
Derry Mercer
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2010/000631 external-priority patent/WO2010112848A2/en
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of BR112012024676A2 publication Critical patent/BR112012024676A2/pt
Publication of BR112012024676B1 publication Critical patent/BR112012024676B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

peptídeo, método para tratar, composição, e, substrato. a presente invenção refere-se aos peptídeos e ao seu uso no tratamento de infecções microbianas, em especial infecções bacterianas. em especial, a invenção refere-se aos peptídeos nos quais pelo menos 75% dos aminoácidos do peptídeo são aminoácidos arginina e fenil-alanina, pelo menos 50% dos aminoácidos sendo aminoácidos arginina e pelo menos 15% dos aminoácidos sendo aminoácidos fenil-alanina.
BR112012024676-3A 2010-03-31 2011-03-30 Peptídeo, composição, e, substrato BR112012024676B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBPCT/GB2010/000631 2010-03-31
PCT/GB2010/000631 WO2010112848A2 (en) 2009-03-31 2010-03-31 Inhibition of biofilm organisms
US39008110P 2010-10-05 2010-10-05
GBGB1016733.6A GB201016733D0 (en) 2010-10-05 2010-10-05 Compounds and their use
US61/390,081 2010-10-05
GB1016733.6 2010-10-05
PCT/GB2011/000480 WO2011121289A2 (en) 2010-03-31 2011-03-30 Compounds and their use

Publications (2)

Publication Number Publication Date
BR112012024676A2 true BR112012024676A2 (pt) 2016-06-07
BR112012024676B1 BR112012024676B1 (pt) 2022-05-03

Family

ID=43243521

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024676-3A BR112012024676B1 (pt) 2010-03-31 2011-03-30 Peptídeo, composição, e, substrato

Country Status (28)

Country Link
US (1) US8901071B2 (pt)
EP (3) EP3479824A3 (pt)
JP (1) JP5969457B2 (pt)
KR (1) KR101922409B1 (pt)
CN (1) CN102906105B (pt)
AU (3) AU2011234252B2 (pt)
BR (1) BR112012024676B1 (pt)
CA (1) CA2797437C (pt)
CY (1) CY1121658T1 (pt)
DK (1) DK2552434T3 (pt)
ES (1) ES2729313T3 (pt)
GB (1) GB201016733D0 (pt)
HR (1) HRP20190982T1 (pt)
HU (1) HUE044549T2 (pt)
IL (1) IL222027A (pt)
LT (1) LT2552434T (pt)
MX (1) MX2012011369A (pt)
NZ (2) NZ603200A (pt)
PL (1) PL2552434T3 (pt)
PT (1) PT2552434T (pt)
RS (1) RS58980B1 (pt)
RU (1) RU2590706C2 (pt)
SG (1) SG184138A1 (pt)
SI (1) SI2552434T1 (pt)
TR (1) TR201908150T4 (pt)
UA (1) UA118167C2 (pt)
WO (1) WO2011121289A2 (pt)
ZA (1) ZA201208173B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201501646PA (en) * 2012-09-07 2015-04-29 Agency Science Tech & Res Peptides and their uses
US20150119345A1 (en) * 2013-10-29 2015-04-30 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of gastrointestinal infections
GB2522412A (en) * 2014-01-22 2015-07-29 Agency Science Tech & Res Antimicrobial peptidomimetics
DE102014101663A1 (de) * 2014-02-11 2015-08-13 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Synthetische artifizielle Peptide mit antimikrobieller Wirkung
GB2524777A (en) * 2014-04-02 2015-10-07 Microarray Ltd Dressing comprising electrodes
US9555057B2 (en) * 2014-09-29 2017-01-31 The Research Foundation For The State University Of New York Compositions and methods for reducing cutaneous microbiome malodor
KR101781679B1 (ko) * 2014-11-21 2017-09-26 한양대학교 산학협력단 수 처리 물질 및 그 제조 방법
WO2017134661A1 (en) * 2016-02-04 2017-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for disrupting biofilms
TWI781963B (zh) 2016-11-09 2022-11-01 俄亥俄州立創新基金會 含二硫化物細胞穿透肽及其製造與使用方法
US11352394B2 (en) 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
JP2020510696A (ja) * 2017-03-03 2020-04-09 ぺプチロジックス,インク. 操作した抗菌性両親媒性ペプチド及びその使用方法
US10744313B2 (en) * 2017-07-27 2020-08-18 University Of Utah Research Foundation Therapeutic delivery device
US11865181B2 (en) * 2017-11-03 2024-01-09 Yale University Peptidic materials that traffic efficiently to the cell cytosol and nucleus
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
CN110227144A (zh) * 2019-06-12 2019-09-13 华懿思科(成都)生物科技有限公司 一种消除妇科炎症致病菌及hpv病毒的抗菌肽靶向制剂及其制备方法
US20230076173A1 (en) * 2020-02-09 2023-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antimicrobial matrix and uses thereof for eliminating microorganisms
CN111533781B (zh) * 2020-03-30 2022-02-08 东北农业大学 非特异受体结合型真菌靶向抗菌肽及其制备方法和应用
WO2022034469A1 (en) * 2020-08-10 2022-02-17 Università Cattolica del Sacro Cuore New antimicrobial peptides
CN112586785B (zh) * 2020-12-03 2022-02-08 青岛大学附属医院 一种驴鞭食用胶原蛋白肽-明胶复合胶囊壁材制备方法
RU2771493C1 (ru) * 2021-04-15 2022-05-05 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Пептид, обладающий антибактериальной активностью в отношении микроорганизмов с множественной лекарственной устойчивостью
CN116606347B (zh) * 2023-04-28 2024-03-29 东北农业大学 一种抗菌肽frrffp及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4635627A (en) 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
WO1994007529A1 (en) 1992-09-25 1994-04-14 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
GB2408263A (en) * 2003-11-14 2005-05-25 Pacgen Biopharmaceuticals Inc Antimicrobial peptides with reduced hemolysis and methods of their use.
EP3141559A1 (en) 2004-08-18 2017-03-15 Novabiotics Limited Antimicrobial peptides
AU2005304115B2 (en) * 2004-11-12 2010-11-18 Novozymes Adenium Biotech A/S Polypeptides having antimicrobial activity and polynucleotides encoding same
WO2007050565A2 (en) * 2005-10-25 2007-05-03 Baylor College Of Medicine Incorporation of antimicrobial combinations onto devices to reduce infection
CN100467481C (zh) * 2006-04-18 2009-03-11 河北师范大学 棕点湍蛙抗菌多肽及其在制药中的应用
CN101070341A (zh) * 2006-05-08 2007-11-14 徐永强 无致突变作用的抗菌多肽
AU2007288080B2 (en) * 2006-08-21 2013-07-04 The University Of British Columbia Small cationic antimicrobial peptides
GB0702021D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
CN101168564B (zh) * 2007-10-22 2012-03-21 中国科学院昆明动物研究所 人源性抗菌肽及其衍生物的用途
EP2168590A1 (en) * 2008-09-24 2010-03-31 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Antimicrobial peptides
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms

Also Published As

Publication number Publication date
HRP20190982T1 (hr) 2019-10-18
RS58980B1 (sr) 2019-08-30
EP3578193A2 (en) 2019-12-11
AU2011234252B2 (en) 2016-05-12
GB201016733D0 (en) 2010-11-17
RU2590706C2 (ru) 2016-07-10
JP5969457B2 (ja) 2016-08-17
AU2011234252A1 (en) 2012-11-22
RU2012145756A (ru) 2014-05-10
SI2552434T1 (sl) 2019-08-30
US8901071B2 (en) 2014-12-02
CN102906105B (zh) 2017-05-10
US20130102524A1 (en) 2013-04-25
EP3479824A3 (en) 2019-08-14
EP3578193C0 (en) 2023-09-06
CA2797437C (en) 2017-11-07
EP3578193A3 (en) 2020-05-20
ES2729313T3 (es) 2019-10-31
TR201908150T4 (tr) 2019-06-21
HUE044549T2 (hu) 2019-11-28
AU2018202201B2 (en) 2019-12-05
EP2552434A2 (en) 2013-02-06
AU2018202201A1 (en) 2018-04-26
AU2016208308B2 (en) 2018-01-18
PT2552434T (pt) 2019-06-12
AU2016208308A1 (en) 2016-08-11
LT2552434T (lt) 2019-07-25
NZ618571A (en) 2015-02-27
JP2013523703A (ja) 2013-06-17
WO2011121289A2 (en) 2011-10-06
IL222027A (en) 2016-11-30
MX2012011369A (es) 2012-11-30
CN102906105A (zh) 2013-01-30
NZ603200A (en) 2014-02-28
BR112012024676B1 (pt) 2022-05-03
EP2552434B1 (en) 2019-05-08
EP3479824A2 (en) 2019-05-08
EP3578193B1 (en) 2023-09-06
PL2552434T3 (pl) 2019-09-30
KR101922409B1 (ko) 2018-11-27
UA118167C2 (uk) 2018-12-10
DK2552434T3 (da) 2019-06-11
CA2797437A1 (en) 2011-10-06
ZA201208173B (en) 2013-07-31
SG184138A1 (en) 2012-10-30
EP2552434B9 (en) 2019-09-11
WO2011121289A3 (en) 2012-03-15
CY1121658T1 (el) 2020-07-31
KR20130043625A (ko) 2013-04-30

Similar Documents

Publication Publication Date Title
BR112012024676A2 (pt) peptídeo, método para tratar, composição, e, substrato
IN2014KN01713A (pt)
IN2014KN01714A (pt)
IN2014KN01716A (pt)
BR112013002729A2 (pt) inibidores de vírus de hepatite c
AR088392A1 (es) Macrociclos peptidomimeticos
BR112013026929A2 (pt) composição e método para intensificação de uma resposta imune
BR112013003101A2 (pt) inibidores do vírus da hepatite c
BR112012012460A2 (pt) &#34;método de liofilização, composições e kits&#34;.
BRPI0713421A2 (pt) Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
BR112013017080A2 (pt) Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
HRP20140185T1 (hr) Peptidi i njihova primjena
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
WO2013105089A8 (en) Anti-inflammatory peptides and use thereof
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
MX2014011614A (es) Fragmentos y proteinas nutritivas con fenilalanina baja o nula y metodos.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112014000542A2 (pt) composições de peroxidase eosinofílica e métodos de uso das mesmas
RS54422B1 (en) APOPTOSIS INHIBITORS AND THEIR USES
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
BR112018070819A2 (pt) peptídeos e composições farmacêuticas, nutracêuticas ou veterinárias para prevenção e/ou tratamento de queda de cabelo
WO2012153337A3 (en) Anti-microbial peptides and uses of same
GB2487299B (en) Method of performing a site-specific chiral inversion in a tripeptide
MY151307A (en) Peptides having antimicrobial activity
ATE453399T1 (de) Isolierte dipeptide mit ace-inhibitionseffekt

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2768 DE 23-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.